Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study

AIM: Locoregional treatment, such as TACE, in combination with immunotherapy may elicit a synergistic anticancer effect. However, TACE combined with atezolizumab plus bevacizumab (atezo/bev) has not been investigated for patients with intermediate stage (BCLC B) HCC beyond the up-to-seven criteria....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Kang, Zhu, Hongfei, Yu, Hongming, Cheng, Yuqiang, Xiang, Yanjun, Cheng, Zhangjun, Li, Yang, Li, Tao, Wang, Dongxu, Zhu, Zhenyu, Cheng, Shuqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122589/
https://www.ncbi.nlm.nih.gov/pubmed/37095751
http://dx.doi.org/10.1155/2023/6353047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122589/
https://www.ncbi.nlm.nih.gov/pubmed/37095751
http://dx.doi.org/10.1155/2023/6353047

Ejemplares similares